Hirayama AV, et al. - Researchers aimed to assess the incidence and durability of responses after CD19-directed chimeric antigen receptor (CAR)-modified T (CAR-T) cell immunotherapy in pts with follicular lymphoma without transformation (FL) or with histologic transformation (tFL). In this phase 1/2 clinical trial, 21 pts with relapsed/refractory (R/R) CD19+ B-cell malignancies were administered CD19 CAR-T cell immunotherapy. The pts reported receipt of cyclophosphamide and fludarabine lymphodepletion followed by 2x10⁶ CD19 CAR-T cells/kg. FL was reported in eight pts (38%) and tFL in 13 (62%). Outcomes support the high efficacy of CD19 CAR-T cell immunotherapy in these adults. FL pts, in a high proportion, showed durable complete remission following this therapy.